RxDoctor Payments DataLook up a doctor →

Nicole Rothman

Family · Durham, NCNPI 1528507704

Payments from drug & device makers

$267,715in general payments, 2019–2025

Across 854 payments — averaging $313.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$247K
  • Biohaven Pharmaceuticals, Inc.$8K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Pfizer$2K
  • Lundbeck LLC$1K
  • plus $4K from 21 others

What the payments were for

  • Consulting fees$3,8601%
  • Speaking & faculty fees$237,91489%
  • Travel & lodging$13,1345%
  • Food & beverage$12,7905%
  • Education$160%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$267,715 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant114$162,141
QuliptaAtogepant106$127,227
Nurtec OdtRimegepant Sulfate90$112,454
BotoxOnabotulinumtoxina68$87,911
Emgality SyringeGalcanezumab-Gnlm37$56,859
Ajovy AutoinjectorFremanezumab-Vfrm23$48,904
Aimovig AutoinjectorErenumab-Aooe52$45,752
Ajovy SyringeFremanezumab-Vfrm41$39,916
Emgality PenGalcanezumab-Gnlm54$38,017
ReyvowLasmiditan Succinate43$32,655
Zembrace SymtouchSumatriptan Succinate11$16,553
Sumatriptan Succinate59$6,024
BelsomraSuvorexant13$5,404
Carbidopa13$3,055
Gabapentin65$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$246,941$377,279288 claims
PfizerNurtec Odt$1,519$112,45490 claims
Lilly USA, LLCReyvow$596$32,65543 claims
Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate$338$16,92658 claims
MerckBelsomra$72$5,40413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →